Cargando…

What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study

(1) Introduction: Since May 2021, sotrovimab has been available in Italy for early treatment of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro studies have questioned its efficacy on Omicron variants. Therefore, we aim to further investigate the efficacy of sotrovima...

Descripción completa

Detalles Bibliográficos
Autores principales: De Vito, Andrea, Colpani, Agnese, Poliseno, Mariacristina, Diella, Lucia, Ieva, Francesco Rosario Paolo, Belati, Alessandra, Papale, Roberto, Babudieri, Sergio, De Santis, Laura, Saracino, Annalisa, Lo Caputo, Sergio, Madeddu, Giordano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458484/
https://www.ncbi.nlm.nih.gov/pubmed/37632099
http://dx.doi.org/10.3390/v15081757
_version_ 1785097176933728256
author De Vito, Andrea
Colpani, Agnese
Poliseno, Mariacristina
Diella, Lucia
Ieva, Francesco Rosario Paolo
Belati, Alessandra
Papale, Roberto
Babudieri, Sergio
De Santis, Laura
Saracino, Annalisa
Lo Caputo, Sergio
Madeddu, Giordano
author_facet De Vito, Andrea
Colpani, Agnese
Poliseno, Mariacristina
Diella, Lucia
Ieva, Francesco Rosario Paolo
Belati, Alessandra
Papale, Roberto
Babudieri, Sergio
De Santis, Laura
Saracino, Annalisa
Lo Caputo, Sergio
Madeddu, Giordano
author_sort De Vito, Andrea
collection PubMed
description (1) Introduction: Since May 2021, sotrovimab has been available in Italy for early treatment of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro studies have questioned its efficacy on Omicron variants. Therefore, we aim to further investigate the efficacy of sotrovimab in real-life settings. (2) Methods: We conducted a retrospective study collecting medical records of people with SARS-CoV-2 infection evaluated in the infectious diseases units of Sassari, Foggia, and Bari, Italy. We included people with SARS-CoV-2 infection treated with sotrovimab and people who did not receive any treatment in 2022. The primary study outcome was to evaluate the efficacy of sotrovimab in reducing disease progression (defined as the necessity of starting oxygen supplementation) and COVID-19-related death. The secondary outcome was to evaluate the safety of sotrovimab. (3) Results: We included 689 people; of them, 341 were treated with sotrovimab, while 348 did not receive any treatment. Overall, we registered 161 (23.4%) disease progressions and 65 (9.4%) deaths, with a significant difference between treated and not-treated people (p < 0.001). In the multivariate logistic regression, increasing age [OR for ten years increasing age 1.23 (95%CI 1.04–1.45)] was associated with a higher risk of disease progression. In addition, cardiovascular disease [OR 1.69 (1.01–2.80), fever [OR 3.88 (95%CI 2.35–6.38)], and dyspnea [OR 7.24 (95%CI 4.17–12.58)] were associated with an increased risk of disease progression. In contrast, vaccination [OR 0.21 (95%CI 0.12–0.37)] and sotrovimab administration [OR 0.05 (95%CI 0.02–0.11)] were associated with a lower risk of developing severe COVID-19. Regarding mortality, people with older age [OR for ten years increasing age 1.36 (95%CI 1.09–1.69)] had a higher risk of death. In addition, in the multivariate analysis, cardiovascular disease lost statistical significance, while people on chemotherapy for haematological cancer [OR 4.07 (95%CI 1.45–11.4)] and those with dyspnea at diagnosis [OR 3.63 (95%CI 2.02–6.50)] had an increased risk of death. In contrast, vaccination [OR 0.37 (95%CI 0.20–0.68)] and sotrovimab treatment [OR 0.16 (95%CI 0.06–0.42)] were associated with lower risk. Only two adverse events were reported; one person complained of diarrhoea a few hours after sotrovimab administration, and one had an allergic reaction with cutaneous rash and itching. (4) Conclusions: Our study showed that sotrovimab treatment was associated with a reduction of the risk of disease progression and death in SARS-CoV-2-infected people, 70% of whom were over 65 years and a with high vaccination rate, with excellent safety. Therefore, our results reinforce the evidence about the efficacy and safety of sotrovimab during the Omicron era in a real-world setting.
format Online
Article
Text
id pubmed-10458484
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104584842023-08-27 What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study De Vito, Andrea Colpani, Agnese Poliseno, Mariacristina Diella, Lucia Ieva, Francesco Rosario Paolo Belati, Alessandra Papale, Roberto Babudieri, Sergio De Santis, Laura Saracino, Annalisa Lo Caputo, Sergio Madeddu, Giordano Viruses Article (1) Introduction: Since May 2021, sotrovimab has been available in Italy for early treatment of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro studies have questioned its efficacy on Omicron variants. Therefore, we aim to further investigate the efficacy of sotrovimab in real-life settings. (2) Methods: We conducted a retrospective study collecting medical records of people with SARS-CoV-2 infection evaluated in the infectious diseases units of Sassari, Foggia, and Bari, Italy. We included people with SARS-CoV-2 infection treated with sotrovimab and people who did not receive any treatment in 2022. The primary study outcome was to evaluate the efficacy of sotrovimab in reducing disease progression (defined as the necessity of starting oxygen supplementation) and COVID-19-related death. The secondary outcome was to evaluate the safety of sotrovimab. (3) Results: We included 689 people; of them, 341 were treated with sotrovimab, while 348 did not receive any treatment. Overall, we registered 161 (23.4%) disease progressions and 65 (9.4%) deaths, with a significant difference between treated and not-treated people (p < 0.001). In the multivariate logistic regression, increasing age [OR for ten years increasing age 1.23 (95%CI 1.04–1.45)] was associated with a higher risk of disease progression. In addition, cardiovascular disease [OR 1.69 (1.01–2.80), fever [OR 3.88 (95%CI 2.35–6.38)], and dyspnea [OR 7.24 (95%CI 4.17–12.58)] were associated with an increased risk of disease progression. In contrast, vaccination [OR 0.21 (95%CI 0.12–0.37)] and sotrovimab administration [OR 0.05 (95%CI 0.02–0.11)] were associated with a lower risk of developing severe COVID-19. Regarding mortality, people with older age [OR for ten years increasing age 1.36 (95%CI 1.09–1.69)] had a higher risk of death. In addition, in the multivariate analysis, cardiovascular disease lost statistical significance, while people on chemotherapy for haematological cancer [OR 4.07 (95%CI 1.45–11.4)] and those with dyspnea at diagnosis [OR 3.63 (95%CI 2.02–6.50)] had an increased risk of death. In contrast, vaccination [OR 0.37 (95%CI 0.20–0.68)] and sotrovimab treatment [OR 0.16 (95%CI 0.06–0.42)] were associated with lower risk. Only two adverse events were reported; one person complained of diarrhoea a few hours after sotrovimab administration, and one had an allergic reaction with cutaneous rash and itching. (4) Conclusions: Our study showed that sotrovimab treatment was associated with a reduction of the risk of disease progression and death in SARS-CoV-2-infected people, 70% of whom were over 65 years and a with high vaccination rate, with excellent safety. Therefore, our results reinforce the evidence about the efficacy and safety of sotrovimab during the Omicron era in a real-world setting. MDPI 2023-08-17 /pmc/articles/PMC10458484/ /pubmed/37632099 http://dx.doi.org/10.3390/v15081757 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Vito, Andrea
Colpani, Agnese
Poliseno, Mariacristina
Diella, Lucia
Ieva, Francesco Rosario Paolo
Belati, Alessandra
Papale, Roberto
Babudieri, Sergio
De Santis, Laura
Saracino, Annalisa
Lo Caputo, Sergio
Madeddu, Giordano
What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
title What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
title_full What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
title_fullStr What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
title_full_unstemmed What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
title_short What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
title_sort what is the efficacy of sotrovimab in reducing disease progression and death in people with covid-19 during the omicron era? answers from a real-life study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458484/
https://www.ncbi.nlm.nih.gov/pubmed/37632099
http://dx.doi.org/10.3390/v15081757
work_keys_str_mv AT devitoandrea whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT colpaniagnese whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT polisenomariacristina whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT diellalucia whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT ievafrancescorosariopaolo whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT belatialessandra whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT papaleroberto whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT babudierisergio whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT desantislaura whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT saracinoannalisa whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT locaputosergio whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy
AT madeddugiordano whatistheefficacyofsotrovimabinreducingdiseaseprogressionanddeathinpeoplewithcovid19duringtheomicroneraanswersfromareallifestudy